<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02132130</url>
  </required_header>
  <id_info>
    <org_study_id>CCGF166X2201</org_study_id>
    <nct_id>NCT02132130</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Efficacy for CGF166 in Patients With Unilateral or Bilateral Severe-to-profound Hearing Loss</brief_title>
  <official_title>A Three-part, Multicenter, Open Label, Single Dose Study to Assess the Safety, Tolerability, and Efficacy of Intra Labyrinthine (IL) CGF166 in Patients With Severe-to-profound Hearing Loss</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of the study was to evaluate the safety, tolerability, and the potential ability of&#xD;
      CGF166 delivered through IL-infusion to improve hearing. CGF166 is a recombinant adenovirus 5&#xD;
      (Ad5) vector containing a cDNA encoding the human Atonal transcription factor (Hath1).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study evaluated the safety, tolerability, and potential efficacy of CGF166 and the&#xD;
      associated delivery procedures in patients with severe-to-profound unilateral or bilateral&#xD;
      hearing loss. Eligible patients were required to have documented, non-fluctuating hearing&#xD;
      loss.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 23, 2014</start_date>
  <completion_date type="Actual">December 9, 2019</completion_date>
  <primary_completion_date type="Actual">December 9, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>week 52</time_frame>
    <description>AE tables are below in the Adverse Events section of this report.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>week 52</time_frame>
    <description>AE tables are below in the Adverse Events section of this report.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Summary of Pure Tone Audiometry in Treated Ear Compared to Pretreatment Values</measure>
    <time_frame>Days 29, 57, 85, 113, 141, 169, 358, 537, 600</time_frame>
    <description>Summary of pure tone audiometry air conduction thresholds at frequency 0.125 KHz</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Summary Pure Tone Audiometry Bone Conduction Thresholds in Treated Ear by Time and Frequency</measure>
    <time_frame>Days 29, 57, 85, 113, 141, 169, 358,537, EoS</time_frame>
    <description>Summary of pure tone audiometry bone conduction thresholds by time and frequency 0.250 KHz</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Summary of Change From Baseline in Treated Ear's Pure Tone Audiometry Air Conduction Threshold by Frequency for Last Study Visit</measure>
    <time_frame>Week 52</time_frame>
    <description>Summary of change from baseline in pure tone audiometry air conduction threshold by frequency for last study visit is presented in table below.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Summary of Change From Baseline in Non-treated Ear's Pure Tone Audiometry Air Conduction Threshold by Frequency for Last Study Visit</measure>
    <time_frame>Week 52</time_frame>
    <description>Summary of change from baseline in Non-treated ear's pure tone audiometry air conduction threshold by frequency for last study visit is presented in table below.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Change in Brainstem Auditory Evoked Responses (BAER) Compared to Pretreatment Values</measure>
    <time_frame>24 months</time_frame>
    <description>BAERs was assessed with standard techniques for clinically significant threshold improvements compared to baseline levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Response in Vestibular Function in Treated Ear Compared to Pretreatment Values</measure>
    <time_frame>24 months</time_frame>
    <description>Response in vestibular assessments (Head impulse test (HIT), Vestibular evoked myogenic potential (VEMP), Subjective visual vertical (SVV)) to CGF166.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Changes in Auditory Functions (Speech Recognition) and Vestibular Functions Before and After IL Infusion of CGF166 Between the Study Ear and the Contralateral Ear</measure>
    <time_frame>24 months</time_frame>
    <description>Clinically signficant speech recognition improvement (word and/or sentence) following treatment. The individual auditory assessments were speech audiometry, AzBio sentence test, consonant nucleus consonant test, word recognition, Hearing-in-Noise Test (HINT), Brainstem auditory evoked response evaluations (BAER), Distortion product otoacoustic emission testing (DPOE) and shoebox audiometry.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Unilateral Severe to Profound Hearing Loss OR Bilateral Severe to Profound Hearing Loss</condition>
  <arm_group>
    <arm_group_label>CGF166 dose 20 uL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose volume #1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CGF166 dose 30 and 40 uL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose volume #2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CGF166 dose 40 uL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose volume #3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CGF166 dose 60 uL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose volume #4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CFG166 dose 30 uL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose volume #5</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CGF166</intervention_name>
    <description>CGF166 is a recombinant adenovirus 5 (Ad5) vector containing the human Atonal transcription factor (Hath1) cDNA for administration via intra-labyrinthine infusion</description>
    <arm_group_label>CFG166 dose 30 uL</arm_group_label>
    <arm_group_label>CGF166 dose 20 uL</arm_group_label>
    <arm_group_label>CGF166 dose 30 and 40 uL</arm_group_label>
    <arm_group_label>CGF166 dose 40 uL</arm_group_label>
    <arm_group_label>CGF166 dose 60 uL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For all Parts A, B and C of the study,&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          1. Written informed consent must be obtained before any assessment is performed.&#xD;
&#xD;
          2. For all Parts A, B and C of the study, male or female patients, 18 to 75 years old,&#xD;
             inclusive, with severe-to-profound bilateral hearing loss or unilateral hearing loss&#xD;
             with intact vestibular function in the nonoperative ear. Non-fluctuating&#xD;
             severe-to-profound hearing loss is required for the study ear and is defined as:&#xD;
&#xD;
               -  PTA within 10 dB of the PTA obtained at least 11 months previously.&#xD;
&#xD;
               -  Word recognition within 20% of previous test at least 11 months previously&#xD;
&#xD;
          3. Candidate ear (&quot;study ear&quot;): Minimal residual hearing based on the pure tone average&#xD;
             of 0.5, 1, 2, and 4 kHz thresholds of ≤110 dB HL&#xD;
&#xD;
          4. Candidate ear (&quot;study ear&quot;): Pure tone audiometric thresholds of ≥50 dB HL for each&#xD;
             testable octave frequency of 0.125 and 0.250 kHz, ≥70 dB HL for each testable octave&#xD;
             frequency from 0.5 through 8 kHz and sentence recognition scores ≤50% at screening.&#xD;
&#xD;
        6. Patients with intact vestibular function in at least one ear (non-study ear) as measured&#xD;
        by vestibular evoked myogenic potential (VEMP) 7. Able to communicate well with the&#xD;
        investigator, to understand and comply with the requirements of the study 8. MRI scan&#xD;
        within 6 months or at screening to confirm suitability for inner ear surgery 9. Patients&#xD;
        must weigh at least 40 kg to participate in the study, and must have a body mass index&#xD;
        (BMI) &lt;45 kg/m2. BMI = Body weight (kg) / [Height (m)]2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with hearing loss caused by genetic/developmental disorders, e.g., cochlea&#xD;
             aplasia&#xD;
&#xD;
          2. Patients with existing conductive hearing loss or mixed hearing loss as judged by the&#xD;
             Principal Investigator following a thorough review of all of the trial hearing&#xD;
             assessments;&#xD;
&#xD;
          3. Patients with a history of cochlear implant in the study ear&#xD;
&#xD;
          4. Hearing loss due to any other cause that would not be expected to respond to hair cell&#xD;
             regeneration, for example mechanical trauma or central auditory lesions or lack of an&#xD;
             auditory nerve&#xD;
&#xD;
          5. Patients who will require ototoxic drugs as routine therapy over the course of the&#xD;
             study, for example cystic fibrosis patients&#xD;
&#xD;
          6. Any contraindication to the planned surgery or anesthesia as determined by the surgeon&#xD;
             or anesthesiologist&#xD;
&#xD;
          7. Previous surgery in the study ear&#xD;
&#xD;
          8. Any otological history, such as chronic otitis, cholesteatoma, tympanic membrane&#xD;
             perforation, that suggests poor candidacy for cochlear implant or inner ear surgery or&#xD;
             suggests potential interference with study auditory or vestibular function tests&#xD;
&#xD;
          9. Pregnant women&#xD;
&#xD;
         10. Abnormal vital signs and/or ECG that suggest potential contraindication for planned&#xD;
             study anesthesia&#xD;
&#xD;
         11. Past serious adverse reaction to anesthesia&#xD;
&#xD;
         12. Meniere's Disease&#xD;
&#xD;
         13. History of radiation therapy to the head and neck&#xD;
&#xD;
         14. Participation in a clinical trial within the last 30 days&#xD;
&#xD;
         15. Immunocompromised patients, as judged by the investigators based on patient history,&#xD;
             physical exam and CBC&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/ctrdweb/patientsummary/patientsummaries?patientSummaryId=680</url>
    <description>A Plain Language Trial Summary is available on novartisclinicaltrials.com</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 5, 2014</study_first_submitted>
  <study_first_submitted_qc>May 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2014</study_first_posted>
  <results_first_submitted>December 2, 2020</results_first_submitted>
  <results_first_submitted_qc>March 3, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 30, 2021</results_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>gene therapy</keyword>
  <keyword>unilateral hearing loss</keyword>
  <keyword>bilateral hearing loss</keyword>
  <keyword>balance</keyword>
  <keyword>vestibular</keyword>
  <keyword>cochlear implant</keyword>
  <keyword>hearing restoration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hearing Loss</mesh_term>
    <mesh_term>Deafness</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.&#xD;
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 30, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/30/NCT02132130/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 17, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/30/NCT02132130/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 22 subjects were enrolled in the study, of which 19 completed the study and 2 subjects discontinued due to lost to follow-up and 1 subject withdrew consent</recruitment_details>
      <pre_assignment_details>Safety analysis set comprised all subjects who received study drug and with no protocol deviations having relevant impact on safety.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>CGF166 Dose 20 μL</title>
          <description>single dose volume #1</description>
        </group>
        <group group_id="P2">
          <title>CGF166 Dose 30 μL</title>
          <description>single dose volume #2</description>
        </group>
        <group group_id="P3">
          <title>CGF166 Dose 40 μL</title>
          <description>single dose volume #3</description>
        </group>
        <group group_id="P4">
          <title>CGF166 Dose 60 μL</title>
          <description>single dose volume #4</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CGF166 Dose 20 μL</title>
          <description>single dose volume #1</description>
        </group>
        <group group_id="B2">
          <title>CGF166 Dose 30 μL</title>
          <description>single dose volume #2</description>
        </group>
        <group group_id="B3">
          <title>CGF166 Dose 40 μL</title>
          <description>single dose volume #3</description>
        </group>
        <group group_id="B4">
          <title>CGF166 Dose 60 μL</title>
          <description>single dose volume #4</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="3"/>
            <count group_id="B5" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.0" spread="17.35"/>
                    <measurement group_id="B2" value="50.8" spread="15.20"/>
                    <measurement group_id="B3" value="52.8" spread="13.40"/>
                    <measurement group_id="B4" value="51.3" spread="19.30"/>
                    <measurement group_id="B5" value="49.6" spread="15.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>AE tables are below in the Adverse Events section of this report.</description>
        <time_frame>week 52</time_frame>
        <population>The Safety Analysis Set was comprised of all subjects that received study drug and with no protocol deviations having relevant impact on safety.</population>
        <group_list>
          <group group_id="O1">
            <title>CGF166 Dose 20 μL</title>
            <description>single dose volume #1</description>
          </group>
          <group group_id="O2">
            <title>CGF166 Dose 30 μLEdit Single Dose Volume #2</title>
            <description>single dose #2</description>
          </group>
          <group group_id="O3">
            <title>CGF166 Dose 40 μL</title>
            <description>single dose volume #3</description>
          </group>
          <group group_id="O4">
            <title>CGF166 Dose 60 μL</title>
            <description>single dose volume #4</description>
          </group>
          <group group_id="O5">
            <title>Total</title>
            <description>Number of participants</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>AE tables are below in the Adverse Events section of this report.</description>
          <population>The Safety Analysis Set was comprised of all subjects that received study drug and with no protocol deviations having relevant impact on safety.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Adverse Events</title>
        <description>AE tables are below in the Adverse Events section of this report.</description>
        <time_frame>week 52</time_frame>
        <population>The Safety Analysis Set was comprised of all subjects that received study drug and with no protocol deviations having relevant impact on safety.</population>
        <group_list>
          <group group_id="O1">
            <title>CGF166 Dose 20 μL</title>
            <description>single dose volume #1</description>
          </group>
          <group group_id="O2">
            <title>CGF166 Dose 30 μL</title>
            <description>single dose volume #2</description>
          </group>
          <group group_id="O3">
            <title>CGF166 Dose 40 μL</title>
            <description>single dose volume #3</description>
          </group>
          <group group_id="O4">
            <title>CGF166 Dose 60 μL</title>
            <description>single dose volume #4</description>
          </group>
          <group group_id="O5">
            <title>Total</title>
            <description>Number of AEs</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Adverse Events</title>
          <description>AE tables are below in the Adverse Events section of this report.</description>
          <population>The Safety Analysis Set was comprised of all subjects that received study drug and with no protocol deviations having relevant impact on safety.</population>
          <units>Adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Summary of Pure Tone Audiometry in Treated Ear Compared to Pretreatment Values</title>
        <description>Summary of pure tone audiometry air conduction thresholds at frequency 0.125 KHz</description>
        <time_frame>Days 29, 57, 85, 113, 141, 169, 358, 537, 600</time_frame>
        <population>Pharmacodynamics (PD) analysis set was comprised of all subjects with any available PD data, who received any study drug and experienced no protocol deviations with relevant impact on PD data.</population>
        <group_list>
          <group group_id="O1">
            <title>CGF166 Dose 20 μL</title>
            <description>single dose volume #1</description>
          </group>
          <group group_id="O2">
            <title>CGF166 Dose 30 μL</title>
            <description>single dose volume #2</description>
          </group>
          <group group_id="O3">
            <title>CGF166 Dose 40 μL</title>
            <description>single dose volume #3</description>
          </group>
          <group group_id="O4">
            <title>CGF166 Dose 60 μL</title>
            <description>single dose volume #4</description>
          </group>
          <group group_id="O5">
            <title>Total</title>
            <description>Number of participants</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Pure Tone Audiometry in Treated Ear Compared to Pretreatment Values</title>
          <description>Summary of pure tone audiometry air conduction thresholds at frequency 0.125 KHz</description>
          <population>Pharmacodynamics (PD) analysis set was comprised of all subjects with any available PD data, who received any study drug and experienced no protocol deviations with relevant impact on PD data.</population>
          <units>DECIBELS</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.3" spread="18.93"/>
                    <measurement group_id="O2" value="70.0" spread="14.62"/>
                    <measurement group_id="O3" value="70.0" spread="20.41"/>
                    <measurement group_id="O4" value="71.7" spread="16.07"/>
                    <measurement group_id="O5" value="69.3" spread="15.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.7" spread="20.82"/>
                    <measurement group_id="O2" value="70.4" spread="22.10"/>
                    <measurement group_id="O3" value="85.0" spread="10.80"/>
                    <measurement group_id="O4" value="75.0" spread="15.00"/>
                    <measurement group_id="O5" value="72.5" spread="19.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.7" spread="20.82"/>
                    <measurement group_id="O2" value="71.4" spread="15.34"/>
                    <measurement group_id="O3" value="86.3" spread="8.54"/>
                    <measurement group_id="O4" value="73.3" spread="15.28"/>
                    <measurement group_id="O5" value="73.1" spread="15.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.7" spread="25.66"/>
                    <measurement group_id="O2" value="66.3" spread="14.36"/>
                    <measurement group_id="O3" value="88.8" spread="24.96"/>
                    <measurement group_id="O4" value="75.0" spread="15.00"/>
                    <measurement group_id="O5" value="73.6" spread="21.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 113</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.0" spread="27.84"/>
                    <measurement group_id="O2" value="73.6" spread="14.33"/>
                    <measurement group_id="O3" value="92.5" spread="23.63"/>
                    <measurement group_id="O4" value="75.0" spread="15.00"/>
                    <measurement group_id="O5" value="75.5" spread="19.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 141</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.0" spread="27.84"/>
                    <measurement group_id="O2" value="68.8" spread="14.93"/>
                    <measurement group_id="O3" value="91.3" spread="22.87"/>
                    <measurement group_id="O4" value="73.3" spread="14.43"/>
                    <measurement group_id="O5" value="74.3" spread="21.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 169</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="72.1" spread="11.85"/>
                    <measurement group_id="O4" value="70.0" spread="7.07"/>
                    <measurement group_id="O5" value="71.7" spread="10.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 358</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="80.0" spread="14.14"/>
                    <measurement group_id="O4" value="72.5" spread="10.61"/>
                    <measurement group_id="O5" value="77.5" spread="12.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 537</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="82.5" spread="10.61"/>
                    <measurement group_id="O4" value="75.0"/>
                    <measurement group_id="O5" value="80.0" spread="8.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 600</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.0" spread="27.84"/>
                    <measurement group_id="O2" value="77.5" spread="15.68"/>
                    <measurement group_id="O3" value="93.8" spread="9.46"/>
                    <measurement group_id="O4" value="82.5" spread="17.68"/>
                    <measurement group_id="O5" value="78.7" spread="18.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Summary Pure Tone Audiometry Bone Conduction Thresholds in Treated Ear by Time and Frequency</title>
        <description>Summary of pure tone audiometry bone conduction thresholds by time and frequency 0.250 KHz</description>
        <time_frame>Days 29, 57, 85, 113, 141, 169, 358,537, EoS</time_frame>
        <population>Pharmacodynamics (PD) analysis set was comprised of all subjects with any available PD data, who received any study drug and experienced no protocol deviations with relevant impact on PD data.</population>
        <group_list>
          <group group_id="O1">
            <title>CGF166 Dose 20 μL</title>
            <description>single dose volume #1</description>
          </group>
          <group group_id="O2">
            <title>CGF166 Dose 30 μL</title>
            <description>single dose volume #2</description>
          </group>
          <group group_id="O3">
            <title>CGF166 Dose 40 μL</title>
            <description>single dose volume #3</description>
          </group>
          <group group_id="O4">
            <title>CGF166 Dose 60 μL</title>
            <description>single dose volume #4</description>
          </group>
          <group group_id="O5">
            <title>Total</title>
            <description>Number of participants</description>
          </group>
        </group_list>
        <measure>
          <title>Summary Pure Tone Audiometry Bone Conduction Thresholds in Treated Ear by Time and Frequency</title>
          <description>Summary of pure tone audiometry bone conduction thresholds by time and frequency 0.250 KHz</description>
          <population>Pharmacodynamics (PD) analysis set was comprised of all subjects with any available PD data, who received any study drug and experienced no protocol deviations with relevant impact on PD data.</population>
          <units>decibels</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.0" spread="0.00"/>
                    <measurement group_id="O2" value="64.2" spread="28.83"/>
                    <measurement group_id="O3" value="87.5" spread="43.5"/>
                    <measurement group_id="O4" value="55.0" spread="0.00"/>
                    <measurement group_id="O5" value="65.9" spread="28.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.0" spread="0.00"/>
                    <measurement group_id="O2" value="73.8" spread="31.49"/>
                    <measurement group_id="O3" value="63.8" spread="42.11"/>
                    <measurement group_id="O4" value="55.0" spread="0.00"/>
                    <measurement group_id="O5" value="66.8" spread="29.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" spread="8.66"/>
                    <measurement group_id="O2" value="56.8" spread="7.83"/>
                    <measurement group_id="O3" value="90.0" spread="40.41"/>
                    <measurement group_id="O4" value="55.0" spread="0.00"/>
                    <measurement group_id="O5" value="61.9" spread="21.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.3" spread="11.55"/>
                    <measurement group_id="O2" value="90.0" spread="40.41"/>
                    <measurement group_id="O3" value="90.0" spread="40.41"/>
                    <measurement group_id="O4" value="51.7" spread="5.77"/>
                    <measurement group_id="O5" value="72.9" spread="34.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 113</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" spread="8.66"/>
                    <measurement group_id="O2" value="57.7" spread="23.17"/>
                    <measurement group_id="O3" value="86.3" spread="45.16"/>
                    <measurement group_id="O4" value="53.3" spread="2.89"/>
                    <measurement group_id="O5" value="61.4" spread="27.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 141</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.7" spread="14.43"/>
                    <measurement group_id="O2" value="51.3" spread="7.50"/>
                    <measurement group_id="O3" value="90.0" spread="40.41"/>
                    <measurement group_id="O4" value="51.7" spread="5.77"/>
                    <measurement group_id="O5" value="61.4" spread="27.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 169</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="48.6" spread="8.52"/>
                    <measurement group_id="O4" value="50.0" spread="7.07"/>
                    <measurement group_id="O5" value="48.9" spread="7.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 358</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="45.0" spread="8.16"/>
                    <measurement group_id="O4" value="55.00" spread="0.00"/>
                    <measurement group_id="O5" value="48.3" spread="8.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 537</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="50" spread="7.07"/>
                    <measurement group_id="O4" value="40"/>
                    <measurement group_id="O5" value="46.7" spread="7.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Study</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.3" spread="11.55"/>
                    <measurement group_id="O2" value="61.5" spread="22.37"/>
                    <measurement group_id="O3" value="90.0" spread="40.41"/>
                    <measurement group_id="O4" value="50.0" spread="7.07"/>
                    <measurement group_id="O5" value="64.2" spread="27.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Summary of Change From Baseline in Treated Ear's Pure Tone Audiometry Air Conduction Threshold by Frequency for Last Study Visit</title>
        <description>Summary of change from baseline in pure tone audiometry air conduction threshold by frequency for last study visit is presented in table below.</description>
        <time_frame>Week 52</time_frame>
        <population>Pharmacodynamics (PD) analysis set was comprised of all subjects with any available PD data, who received any study drug and experienced no protocol deviations with relevant impact on PD data.</population>
        <group_list>
          <group group_id="O1">
            <title>CGF166 Dose 20 μL</title>
            <description>single dose volume #1</description>
          </group>
          <group group_id="O2">
            <title>CGF166 Dose 30 μL</title>
            <description>single dose volume #2</description>
          </group>
          <group group_id="O3">
            <title>CGF166 Dose 40 μL</title>
            <description>single dose volume #3</description>
          </group>
          <group group_id="O4">
            <title>CGF166 Dose 60 μL</title>
            <description>single dose volume #4</description>
          </group>
          <group group_id="O5">
            <title>Total</title>
            <description>Number of participants</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Change From Baseline in Treated Ear's Pure Tone Audiometry Air Conduction Threshold by Frequency for Last Study Visit</title>
          <description>Summary of change from baseline in pure tone audiometry air conduction threshold by frequency for last study visit is presented in table below.</description>
          <population>Pharmacodynamics (PD) analysis set was comprised of all subjects with any available PD data, who received any study drug and experienced no protocol deviations with relevant impact on PD data.</population>
          <units>decibels</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>125 hz</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.2" spread="9.46"/>
                    <measurement group_id="O2" value="6.7" spread="10.19"/>
                    <measurement group_id="O3" value="26.3" spread="17.02"/>
                    <measurement group_id="O4" value="5.0" spread="4.33"/>
                    <measurement group_id="O5" value="8.5" spread="13.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>250 Hz</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.3" spread="6.29"/>
                    <measurement group_id="O2" value="6.0" spread="9.20"/>
                    <measurement group_id="O3" value="26.3" spread="26.65"/>
                    <measurement group_id="O4" value="0.8" spread="1.44"/>
                    <measurement group_id="O5" value="7.7" spread="15.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>500 Hz</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="5.00"/>
                    <measurement group_id="O2" value="7.7" spread="11.00"/>
                    <measurement group_id="O3" value="26.3" spread="23.32"/>
                    <measurement group_id="O4" value="0.8" spread="1.44"/>
                    <measurement group_id="O5" value="9.1" spread="14.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1,000 Hz</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="3.82"/>
                    <measurement group_id="O2" value="8.1" spread="10.51"/>
                    <measurement group_id="O3" value="16.9" spread="8.98"/>
                    <measurement group_id="O4" value="5.8" spread="1.44"/>
                    <measurement group_id="O5" value="8.2" spread="9.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2,000 Hz</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="6.29"/>
                    <measurement group_id="O2" value="6.0" spread="11.40"/>
                    <measurement group_id="O3" value="6.9" spread="8.51"/>
                    <measurement group_id="O4" value="0.8" spread="3.82"/>
                    <measurement group_id="O5" value="4.8" spread="9.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3,000 Hz</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="2.50"/>
                    <measurement group_id="O2" value="5.8" spread="11.60"/>
                    <measurement group_id="O3" value="11.9" spread="11.06"/>
                    <measurement group_id="O4" value="-4.2" spread="3.82"/>
                    <measurement group_id="O5" value="5.1" spread="10.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4,000 Hz</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="1.44"/>
                    <measurement group_id="O2" value="4.4" spread="12.97"/>
                    <measurement group_id="O3" value="5.0" spread="4.08"/>
                    <measurement group_id="O4" value="-0.8" spread="3.82"/>
                    <measurement group_id="O5" value="3.3" spread="9.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6,000 Hz</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="2.89"/>
                    <measurement group_id="O2" value="3.3" spread="13.16"/>
                    <measurement group_id="O3" value="7.5" spread="15.00"/>
                    <measurement group_id="O4" value="1.7" spread="6.29"/>
                    <measurement group_id="O5" value="3.2" spread="11.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8,000 Hz</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="2.89"/>
                    <measurement group_id="O2" value="2.9" spread="15.33"/>
                    <measurement group_id="O3" value="-8.8" spread="17.50"/>
                    <measurement group_id="O4" value="4.2" spread="7.22"/>
                    <measurement group_id="O5" value="0.8" spread="13.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Summary of Change From Baseline in Non-treated Ear's Pure Tone Audiometry Air Conduction Threshold by Frequency for Last Study Visit</title>
        <description>Summary of change from baseline in Non-treated ear's pure tone audiometry air conduction threshold by frequency for last study visit is presented in table below.</description>
        <time_frame>Week 52</time_frame>
        <population>Pharmacodynamics (PD) analysis set was comprised of all subjects with any available PD data, who received any study drug and experienced no protocol deviations with relevant impact on PD data.</population>
        <group_list>
          <group group_id="O1">
            <title>CGF166 Dose 20 μL</title>
            <description>single dose volume #1</description>
          </group>
          <group group_id="O2">
            <title>CGF166 Dose 30 μL</title>
            <description>single dose volume #2</description>
          </group>
          <group group_id="O3">
            <title>CGF166 Dose 40 μL</title>
            <description>single dose volume #3</description>
          </group>
          <group group_id="O4">
            <title>CGF166 Dose 60 μL</title>
            <description>single dose volume #4</description>
          </group>
          <group group_id="O5">
            <title>Total</title>
            <description>Number of participants</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Change From Baseline in Non-treated Ear's Pure Tone Audiometry Air Conduction Threshold by Frequency for Last Study Visit</title>
          <description>Summary of change from baseline in Non-treated ear's pure tone audiometry air conduction threshold by frequency for last study visit is presented in table below.</description>
          <population>Pharmacodynamics (PD) analysis set was comprised of all subjects with any available PD data, who received any study drug and experienced no protocol deviations with relevant impact on PD data.</population>
          <units>decibels</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>125 hz</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" spread="6.61"/>
                    <measurement group_id="O2" value="1.7" spread="4.92"/>
                    <measurement group_id="O3" value="-3.1" spread="2.39"/>
                    <measurement group_id="O4" value="-1.7" spread="3.82"/>
                    <measurement group_id="O5" value="8.5" spread="4.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>250 Hz</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="8.66"/>
                    <measurement group_id="O2" value="2.3" spread="5.48"/>
                    <measurement group_id="O3" value="-2.5" spread="3.54"/>
                    <measurement group_id="O4" value="0.8" spread="2.89"/>
                    <measurement group_id="O5" value="7.7" spread="5.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>500 Hz</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="1.44"/>
                    <measurement group_id="O2" value="6.0" spread="18.87"/>
                    <measurement group_id="O3" value="-2.5" spread="3.54"/>
                    <measurement group_id="O4" value="-1.7" spread="2.50"/>
                    <measurement group_id="O5" value="9.1" spread="14.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1,000 Hz</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="2.89"/>
                    <measurement group_id="O2" value="1.7" spread="4.81"/>
                    <measurement group_id="O3" value="0" spread="2.04"/>
                    <measurement group_id="O4" value="-1.7" spread="1.44"/>
                    <measurement group_id="O5" value="8.2" spread="3.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2,000 Hz</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="2.89"/>
                    <measurement group_id="O2" value="0.2" spread="7.27"/>
                    <measurement group_id="O3" value="-0.6" spread="2.39"/>
                    <measurement group_id="O4" value="-2.5" spread="4.33"/>
                    <measurement group_id="O5" value="4.8" spread="5.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3,000 Hz</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="5.00"/>
                    <measurement group_id="O2" value="0.2" spread="4.94"/>
                    <measurement group_id="O3" value="0.6" spread="1.25"/>
                    <measurement group_id="O4" value="-7.5" spread="2.50"/>
                    <measurement group_id="O5" value="5.1" spread="4.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4,000 Hz</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" spread="6.61"/>
                    <measurement group_id="O2" value="1.0" spread="3.76"/>
                    <measurement group_id="O3" value="1.3" spread="2.50"/>
                    <measurement group_id="O4" value="-0.8" spread="6.29"/>
                    <measurement group_id="O5" value="3.3" spread="4.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6,000 Hz</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="1.44"/>
                    <measurement group_id="O2" value="-0.6" spread="3.56"/>
                    <measurement group_id="O3" value="-8.1" spread="11.79"/>
                    <measurement group_id="O4" value="-1.7" spread="5.77"/>
                    <measurement group_id="O5" value="3.2" spread="6.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8,000 Hz</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.3" spread="5.77"/>
                    <measurement group_id="O2" value="-4.2" spread="10.78"/>
                    <measurement group_id="O3" value="-8.8" spread="17.50"/>
                    <measurement group_id="O4" value="-0.8" spread="6.29"/>
                    <measurement group_id="O5" value="0.8" spread="10.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Change in Brainstem Auditory Evoked Responses (BAER) Compared to Pretreatment Values</title>
        <description>BAERs was assessed with standard techniques for clinically significant threshold improvements compared to baseline levels.</description>
        <time_frame>24 months</time_frame>
        <population>PD analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>CGF166 Dose 20 μL</title>
            <description>single dose volume #1</description>
          </group>
          <group group_id="O2">
            <title>CGF166 Dose 30 μL</title>
            <description>single dose volume #2</description>
          </group>
          <group group_id="O3">
            <title>CGF166 Dose 40 μL</title>
            <description>single dose volume #3</description>
          </group>
          <group group_id="O4">
            <title>CGF166 Dose 60 μL</title>
            <description>single dose volume #4</description>
          </group>
          <group group_id="O5">
            <title>Total</title>
            <description>Number of participants</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Change in Brainstem Auditory Evoked Responses (BAER) Compared to Pretreatment Values</title>
          <description>BAERs was assessed with standard techniques for clinically significant threshold improvements compared to baseline levels.</description>
          <population>PD analysis set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Response in Vestibular Function in Treated Ear Compared to Pretreatment Values</title>
        <description>Response in vestibular assessments (Head impulse test (HIT), Vestibular evoked myogenic potential (VEMP), Subjective visual vertical (SVV)) to CGF166.</description>
        <time_frame>24 months</time_frame>
        <population>PD Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>CGF166 Dose 20 μL</title>
            <description>single dose volume #1</description>
          </group>
          <group group_id="O2">
            <title>CGF166 Dose 30 μL</title>
            <description>single dose volume #2</description>
          </group>
          <group group_id="O3">
            <title>CGF166 Dose 40 μL</title>
            <description>single dose volume #3</description>
          </group>
          <group group_id="O4">
            <title>CGF166 Dose 60 μL</title>
            <description>single dose volume #4</description>
          </group>
          <group group_id="O5">
            <title>Total</title>
            <description>Number of participants</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Response in Vestibular Function in Treated Ear Compared to Pretreatment Values</title>
          <description>Response in vestibular assessments (Head impulse test (HIT), Vestibular evoked myogenic potential (VEMP), Subjective visual vertical (SVV)) to CGF166.</description>
          <population>PD Analysis Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Changes in Auditory Functions (Speech Recognition) and Vestibular Functions Before and After IL Infusion of CGF166 Between the Study Ear and the Contralateral Ear</title>
        <description>Clinically signficant speech recognition improvement (word and/or sentence) following treatment. The individual auditory assessments were speech audiometry, AzBio sentence test, consonant nucleus consonant test, word recognition, Hearing-in-Noise Test (HINT), Brainstem auditory evoked response evaluations (BAER), Distortion product otoacoustic emission testing (DPOE) and shoebox audiometry.</description>
        <time_frame>24 months</time_frame>
        <population>PD analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>CGF166 Dose 20 μL</title>
            <description>single dose volume #1</description>
          </group>
          <group group_id="O2">
            <title>CGF166 Dose 30 μL</title>
            <description>single dose volume #2</description>
          </group>
          <group group_id="O3">
            <title>CGF166 Dose 40 μL</title>
            <description>single dose volume #3</description>
          </group>
          <group group_id="O4">
            <title>CGF166 Dose 60 μL</title>
            <description>single dose volume #4</description>
          </group>
          <group group_id="O5">
            <title>Total</title>
            <description>Total Number of participants</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Changes in Auditory Functions (Speech Recognition) and Vestibular Functions Before and After IL Infusion of CGF166 Between the Study Ear and the Contralateral Ear</title>
          <description>Clinically signficant speech recognition improvement (word and/or sentence) following treatment. The individual auditory assessments were speech audiometry, AzBio sentence test, consonant nucleus consonant test, word recognition, Hearing-in-Noise Test (HINT), Brainstem auditory evoked response evaluations (BAER), Distortion product otoacoustic emission testing (DPOE) and shoebox audiometry.</description>
          <population>PD analysis set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AEs) were collected from first dose of study treatment until end of study treatment at 52 weeks</time_frame>
      <desc>AEs are any untoward sign or symptom that occurs during the study treatment</desc>
      <group_list>
        <group group_id="E1">
          <title>CGF166 20 μL</title>
          <description>CCGF166X2201 20 μL</description>
        </group>
        <group group_id="E2">
          <title>CGF166 30 μL</title>
          <description>CCGF166X2201 30 μL</description>
        </group>
        <group group_id="E3">
          <title>CGF166 40 μL</title>
          <description>CCGF166X2201 40 μL</description>
        </group>
        <group group_id="E4">
          <title>CGF166 60 μL</title>
          <description>CCGF166X2201 60 μL</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA (22.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Left ventricular hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness unilateral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Ear haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Hypoacusis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Tympanic membrane disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Vestibular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Food allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Vestibular neuronitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Electrocardiogram T wave abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Nystagmus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Vestibular migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermal cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>+1 (862) 778-8300</phone>
      <email>novartis.email@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

